$OTIC News

Last published 3y ago

3y agoOTICOtonomy Announces Change in Stock Exchange ListingGlobeNewswireSAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the
3y agoOTICOtonomy Provides Corporate UpdateGlobeNewswireSAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that the company's board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and
4y agoOTICOtonomy Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireSAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the
4y agoOTICOtonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing LossGlobeNewswireHigher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg dose evaluated in prior studies may be due to a complex dose-response
4y agoOTICOtonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with TinnitusGlobeNewswireOTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepoints Company to discontinue development of OTO-313 and implement other measures to extend its cash runway Clinical focus shi
4y agoOTICOtonomy Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireTop-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022 Positive top-l
4y agoOTICOtonomy (OTIC) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsOTIC earnings call for the period ending June 30, 2022.
4y agoOTICOtonomy to Report Second Quarter 2022 Financial Results and Provide Corporate UpdateGlobeNewswireSAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 202
4y agoOTICOtonomy to Participate in the H.C. Wainwright Global Investment ConferenceGlobeNewswireSAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright Global Investment C
4y agoOTICOtonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual MeetingGlobeNewswireSAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of preclinical data for OTO-825 at the upcom
4y agoOTICOtonomy Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswirePositive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluation OTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher
4y agoOTICOtonomy (OTIC) Q1 2022 Earnings Call TranscriptEarnings Call TranscriptsOTIC earnings call for the period ending March 31, 2022.
4y agoOTICOtonomy to Report First Quarter 2022 Financial Results and Provide Corporate UpdateGlobeNewswireSAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2022 a
4y agoOTICOtonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing LossGlobeNewswireClinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability findings from previous Phase 1/2 trial Enrollment in high
4y agoOTICOtonomy to Host Virtual Investor R&D Event on March 22, 2022GlobeNewswireSAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it will host a virtual Investor R&D Event from 10 a.m.
4y agoOTICOtonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswireOTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosing OTO-413 Phase 2a cohort in hearing loss fully enrolled with top-line results expe
4y agoOTICOtonomy (OTIC) Q4 2021 Earnings Call TranscriptEarnings Call TranscriptsOTIC earnings call for the period ending December 31, 2021.
4y agoOTICOtonomy to Participate in Two Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management will participate in the following virtual in
4y agoOTICOtonomy to Host Virtual Investor R&D Event on March 22, 2022GlobeNewswireSAN DIEGO, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it will host a virtual Investor R&D Event from 10 a.m.
4y agoOTICOtonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in TinnitusGlobeNewswireOTO-313 Phase 2 trial is fully enrolled ahead of schedule Top-line results for all timepoints expected in mid-2022 SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development
4y agoOTICOtonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate UpdateGlobeNewswireSAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and
4y agoOTICOtonomy Announces OTO-413 Presentations at American Auditory Society Annual MeetingGlobeNewswireSAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced two upcoming presentations on the OTO-413 hearing loss pro
4y agoOTICOtonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual MeetingGlobeNewswireSAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Resea
4y agoOTICOtonomy Reports Corporate and Product Pipeline UpdateGlobeNewswireMultiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022 Current capital funds operations into second half of 2023 SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biop
4y agoOTICOtonomy to Participate in the H.C. Wainwright BioConnect ConferenceGlobeNewswireSAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright BioConnect Virtual
5y agoAGTC OTICOtonomy Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireOTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022 Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter of 2022 Initiating clinical safety evaluation of hi
5y agoOTICOtonomy to Report Third Quarter 2021 Financial Results and Provide Corporate UpdateGlobeNewswireSAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter 2021
5y agoOTICOtonomy Announces Multiple Presentations at Neuroscience 2021 MeetingGlobeNewswirePresentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss Supportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection program SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIR
5y agoOTICOtonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313GlobeNewswireResults published in Otology & Neurotology, a leading journal in field OTO-313 was well-tolerated and demonstrated a statistically significant higher proportion of responders than placebo across consecutive visits (Weeks 4 and 8) Patient enrollment in
5y agoOTICOtonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual MeetingGlobeNewswireSAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results f
5y agoOTICOtonomy to Participate in Two Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in two upcoming
5y agoOTICOtonomy Appoints Jill Broadfoot to Board of DirectorsGlobeNewswireSAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors.
5y agoAGTC OTICOtonomy Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireOTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022 OTO-413 Phase 1/2 trial expansion in hearing loss ongoing with results expected in mid-2022 OTO-825 preclinical proof-of-concept results presented at ASGCT meeting; Pre-IND me
5y agoOTICOtonomy to Report Second Quarter 2021 Financial Results and Provide Corporate UpdateGlobeNewswireSAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2021
5y agoOTICOtonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing LossGlobeNewswireOTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests in dose escalation efficacy cohort Expansion study will support endpoint selection and powering for Phase 2 Top-line results expected i
5y agoAGTC OTICOtonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual MeetingGlobeNewswireSAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical proof-of-concept results for OTO-825 presented at
5y agoOTICOtonomy Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireOTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022 OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in mid-2022 OTO-825 IND-enabling activities underway w
5y agoOTICOtonomy, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 11, 2021 / Otonomy, Inc. (NASDAQ:OTIC) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 11, 2021 at 4:30 PM Eastern Time. To listen to the event live or access a replay
5y agoOTICOtonomy to Report First Quarter 2021 Financial Results and Provide Corporate UpdateGlobeNewswireSAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2021 a
5y agoAGTC OTICOtonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual MeetingGlobeNewswireSAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the upcoming presentation of preclinical proof-of-concept d
5y agoOTICOtonomy Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireSAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closing of its previously announced underwritten public
5y agoOTICOtonomy Announces Pricing of $30.1 Million Public OfferingGlobeNewswireSAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
5y agoOTICOtonomy Announces Proposed Public OfferingGlobeNewswireSAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
5y agoOTICOtonomy to Present at the Needham Virtual Healthcare ConferenceGlobeNewswireSAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
5y agoOTICOtonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual MeetingGlobeNewswireSAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
5y agoOTICOTO-313 in Subjects With Unilateral Subjective Tinnitus - NCT04829214ClinicalTrials.govChange from Baseline in Tinnitus Functional Index (TFI), Daily Tinnitus Loudness, Daily Tinnitus Annoyance, Patient Global Impression of Change
5y agoOTICOtonomy Initiates Phase 2 Clinical Trial of OTO-313 in TinnitusGlobeNewswirePhase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for primary efficacy endpointPatient enrollment criteria refined to enrich...
5y agoOTICOtonomy to Participate in Three Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
5y agoOTICOtonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's DiseaseGlobeNewswireSAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
5y agoOTICOtonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual MeetingGlobeNewswirePresentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing lossSupportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection...